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The National Cancer Imaging Translational Accelerator (NCITA) is creating a UK national coordinated infrastructure for accelerated
translation of imaging biomarkers for clinical use. Through the development of standardised protocols, data integration tools and
ongoing training programmes, NCITA provides a unique scalable infrastructure for imaging biomarker qualification using
multicentre clinical studies.
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Imaging biomarkers have potential to provide objective, minimally
invasive tools for the diagnosis and therapeutic management of
tumours, including quantitative assessment of tissue microstruc-
ture, metabolism and function. However, clinical imaging within
healthcare systems remains largely limited to assessment of
anatomical changes in tumour size, with a few notable exceptions
such as assessment of tumour metabolism using positron
emission tomography (PET) with 2-deoxy-2-[fluorine-18]fluoro-D-
glucose integrated with computed tomography ([18F]FDG PET-CT)
[1, 2]. This gap between translatable imaging biomarker research
and clinical application reflects the challenges in crossing two key
‘translational gaps’ [3, 4]; namely translation of promising
candidates into fully validated and standardised products and
the provision of robust evidence to support their implementation
and adoption into clinical practice [5]. For complex multicentre
imaging biomarker studies, differences in imaging sequences for
different scanners, field strengths and vendors and inter- and
intra-observer variability in image acquisition and analysis pose
significant challenges for standardisation. Here, we outline a new
coordinated infrastructure designed to accelerate the clinical
translation of robust and reproducible imaging biomarkers to
transform cancer diagnosis and improve healthcare outcomes for
patients.
The National Cancer Imaging Translational Accelerator (NCITA)
is a clinical imaging research consortium, which is creating the
necessary integrated infrastructure to accelerate robust qualifica-
tion of cancer imaging biomarkers for clinical use, as proposed in
the Imaging Biomarker Roadmap for Cancer Studies [5]. Estab-
lished in 2019, through Cancer Research UK (CRUK) Accelerator
award funding, NCITA builds on previous Cancer Imaging Centres
Initiatives (2008–2018), funded by CRUK and the Engineering and
Physical Sciences Research Council (EPSRC), which were pivotal in
driving innovation in biomarker research using novel imaging
techniques [6–11]. NCITA brings together nine UK centres of
excellence for medical imaging, namely, University College
London, The University of Manchester, University of Oxford, King’s
College London, The Institute of Cancer Research (ICR), Imperial
College London, University of Cambridge, University of Glasgow
and Newcastle University (Supplementary 1). This multi-
institutional collaborative network includes medical imaging
experts, clinical oncologists, physicists and research scientists
who are developing standardised imaging biomarker qualification
pipelines to accelerate the development of qualified imaging
biomarkers using multicentre studies.
The NCITA infrastructure includes three cross-institutional units
(imaging clinical trials unit (CTU), quality assurance/quality control
(QA/QC) and repository units) and three activity groups (engage-
ment, training and contracts management), which together with
the Governance Group, work in synergy to facilitate cross-sector
translational imaging biomarker research. The goals of NCITA are
to establish standardised protocols and locked-down quality-
assured processes for imaging biomarker qualification and a
federated research data repository for secure data storage and
sharing between study sites. The repository incorporates auto-
mated QA and post-hoc computational image analysis using
containerised workflows, novel machine learning and artificial
intelligence (AI) tools (Fig. 1). To improve study efficiencies, NCITA
is developing unified contracts, policies and standard operating
procedures that transcend individual institutions. Through
engagement with key imaging stakeholders, NCITA will develop
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consensus guidelines for robust qualification of imaging biomar-
kers to instill reliability in the development pathway and
accelerate clinical adoption. NCITA also organises ongoing work-
shops, events and online training materials to ensure that the
valuable skills and expertise of the NCITA workforce are
sustainable and scalable.
NCITA supports a portfolio of Exemplar studies, selected to
demonstrate the effectiveness of the infrastructure in accelerating
qualification and translation of these promising imaging biomar-
kers (Supplemental Table). NCITA infrastructure support is also
accessible to external clinical researchers from academia and
industry through NCITA’s study adoption process. International
partners are also eligible to apply. For example, NCITA provides
repository support for CRUK International Alliance for Cancer Early
Detection (ACED), which includes partners at Stanford University
and Oregon Health and Science University, USA. Researchers are
encouraged to contact NCITA early during study development by
email (ncita.general@ucl.ac.uk) or via the website (ncita.org.uk/
contact), preferably prior to applying for grant funding. While
cancer imaging studies are a key focus, clinical research studies in
other disease areas involving AI algorithm development, training
and validation will be considered, especially if these studies are
thought to benefit AI algorithm development for future early
cancer detection studies. Study applications are reviewed by the
programme and unit managers and the governance group to
assess the quality of the study proposal, funding plans and status
(Supplementary 2). Where studies are successfully adopted, a
representative from the new institution or company will be
encouraged to join the relevant NCITA management, trial steering
committee or consensus group to facilitate knowledge transfer
and potential growth of the required infrastructure.
Early phase observational and validation-based studies as well as
later phase interventional and therapeutic studies are supported by
the NCITA CTU using a range of imaging technologies, including
whole-body MRI, hyperpolarised 13C MRI, multi-parametric MRI,
oxygen-enhanced MRI, PET, PET-MRI and PET-CT. The NCITA CTU
complements local study infrastructure and provides an adaptable
governance framework that can be tailored to the study develop-
ment phase. This bespoke service provides excellent value for
money and aids smoother funding applications and approvals. This
is especially important for observational imaging studies, which are
often deprioritised when competing for limited National Institute for
Health Research (NIHR) infrastructure support, in favour of interven-
tional cancer studies.
The QA/QC Unit supports study setup, technical and biological
validation, protocol development and staged lockdown of
standardised image acquisition, processing and analysis meth-
odologies. Efficient management of site equipment, process
documentation, workflows, audits, training and continuous quality
improvements across study sites is facilitated by a centralised
quality management system. The QA/QC Unit is also establishing a
national MRI Core Lab, to support site evaluation, site qualification
and performance monitoring for MRI multicentre studies (Supple-
mentary 3). This will help to elevate the quality of MRI biomarkers
and improve translation efficiency. For NCITA PET imaging studies,
NCITA will liaise closely with the UK PET Core Lab at St Thomas’
Hospital London to ensure the studies are performed to agreed
standards.
The Repository Unit is developing a sustainable, cross-
institutional federated repository structure for secure data storage,
integration, analysis and sharing. The repository is based on an
eXtensible Neuroimaging Archive Toolkit (XNAT) prototype,
originally built and hosted by the ICR [12] under the aegis of
ICR’s CRUK-EPSRC Cancer Imaging Centre, and related work at the
CRUK Cambridge Institute. The repository supports short- or long-
term secure data archival, and encompasses the full range of data
maturity including initial data acquisition, through various levels of
data curation, to controlled release of deidentified data as a
community resource. For example, the NCITA repository already
contains a large COVID database including the UK National Covid-
19 Chest Imaging Database (NCCID). The repository will be
interoperable with and receive data directly from the National
Health Service (NHS), including NHS Digital’s Trusted Research
Environment services.
DICOM data







Fig. 1 High-level schematic overview of the NCITA Image Repository Unit. Clinical study data from both DICOM and non-DICOM modalities
are curated securely, enabling users to perform both automated data quality assurance (thus improving data harmonisation) and bespoke
analysis using containerised workflows, including novel AI tools. Processing outputs will be stored back in the repository with complete
provenance. Cohort-building tools, which may use natural language processing or content-based image retrieval, together with enhanced
visualisation, will allow clinicians and scientists to participate in virtual tumour boards, to enable collaborative knowledge sharing and
communication for improving clinical interpretation of complex imaging biomarker readouts.
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NCITA’s data sharing solutions are based on the FAIR principles
[13], that data are findable, accessible, interoperable and reusable.
For NCITA’s adopted studies, streamlined data access procedures
will enable data sharing, including an approach to the relevant
Ethics and Trial Steering Committees. For non-NCITA sites, data
access will involve an application process and will be regulated by
audited procedures. Open-access data resources will also be
developed for the imaging research community worldwide.
The Repository and QA/QC Units are developing quality-assured
pipelines for imaging biomarker qualification from source image
data. Recent work includes implementation of the VERDICT
technique [14], radiomics pipelines in line with International
Biomarker Standardisation Initiative guidelines [15] and a plugin
to enable automatic assessment of incoming imaging datasets to
determine compliance with study protocols. The Repository Unit is
also developing AI-assisted image annotation for radiologists,
linking of curated imaging datasets to publications and genera-
tion of datasets for AI development. The Repository Unit is also
engaged in the release lifecycle of XNAT and is the integrator of
the Open Health Imaging Foundation (OHIF) viewer into XNAT
[16], which provides a flexible framework for building web-based
imaging applications to support clinical imaging research.
A key goal for NCITA is to generate consensus on how the
imaging biomarker development pathway can be improved to
achieve more efficient translation of quality-assured imaging
biomarkers into clinical practice. The NCITA Engagement Group
are engaging with key imaging stakeholders, to facilitate the
establishment of a consensus group to agree and publish
recommendations for accelerating robust qualification and adop-
tion of imaging biomarkers for clinical use. The Engagement
Group also facilitates clinical researchers from academia and
industry to access the NCITA infrastructure and works closely with
CRUK’s Commercial Partnerships team to ensure translational
support for new discoveries arising from exemplar projects and
other projects supported by CRUK. Other engagement activities
include dissemination of news, events and information through
the NCITA website (https://www.ncita.org.uk), social media
accounts (NCITA Imaging (@imaging_cancer)|Twitter and Linke-
dIn), press releases and publications.
During the 5-year CRUK Accelerator Award, NCITA will have
established the necessary integrated infrastructure to facilitate
accelerated translation of imaging biomarkers for clinical applica-
tion. To ensure continued growth and sustainability, NCITA will
link with NHS initiatives including the NIHR Biomedical Research
Council/Clinical Research Network and NIHR Imaging Group, as
well as funding bodies, charities and industrial partnerships. The
sustainability of NCITA will have significant benefits in streamlin-
ing future clinical imaging studies and providing ongoing training
of a new generation of highly skilled medical imaging researchers




1. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al.
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J
Nucl Med Mol Imaging. 2015;42:328–54.
2. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al.
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med.
2008;49:480–508.
3. Black N. The Cooksey review of UK health research funding. BMJ.
2006;333:1231–2.
4. Sung NS, Crowley WF Jr, Genel M, Salber P, Sandy L, Sherwood LM, et al. Central
challenges facing the national clinical research enterprise. JAMA.
2003;289:1278–87.
5. O’Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, et al.
Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol.
2017;14:169–86.
6. Sharma R, Aboagye E. Development of radiotracers for oncology-the interface
with pharmacology. Br J Pharmacol. 2011;163:1565–85.
7. Scarsbrook AF, Bottomley D, Teoh EJ, Bradley KM, Payne H, Afaq A, et al. Effect of
(18)F-fluciclovine positron emission tomography on the management of patients
with recurrence of prostate cancer: results from the FALCON trial. Int J Radiat
Oncol Biol Phys. 2020;107:316–24.
8. Arulappu A, Battle M, Eisenblaetter M, McRobbie G, Khan I, Monypenny J, et al. c-
Met PET imaging detects early-stage locoregional recurrence of basal-like breast
cancer. J Nucl Med. 2016;57:765–70.
9. Diocou S, Volpe A, Jauregui-Osoro M, Boudjemeline M, Chuamsaamarkkee K, Man F,
et al. [(18)F]tetrafluoroborate-PET/CT enables sensitive tumor and metastasis in vivo
imaging in a sodium iodide symporter-expressing tumor model. Sci Rep. 2017;7:946.
10. Eisenblaetter M, Flores-Borja F, Lee JJ, Wefers C, Smith H, Hueting R, et al.
Visualization of tumor-immune interaction—-target-specific imaging of S100A8/
A9 reveals pre-metastatic niche establishment. Theranostics. 2017;7:2392–401.
11. Salem A, Little RA, Latif A, Featherstone AK, Babur M, Peset I, et al. Oxygen-
enhanced MRI is feasible, repeatable, and detects radiotherapy-induced change
in hypoxia in xenograft models and in patients with non-small cell lung cancer.
Clin Cancer Res. 2019;25:3818–29.
12. Doran SJ, d’Arcy J, Collins DJ, Andriantsimiavona R, Orton M, Koh DM, et al.
Informatics in radiology: development of a research PACS for analysis of func-
tional imaging data in clinical research and clinical trials. Radiographics.
2012;32:2135–50.
13. Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, et al.
The FAIR Guiding Principles for scientific data management and stewardship. Sci
Data. 2016;3:160018.
14. Bonet-Carne E, Johnston E, Daducci A, Jacobs JG, Freeman A, Atkinson D, et al.
VERDICT-AMICO: Ultrafast fitting algorithm for non-invasive prostate micro-
structure characterization. NMR Biomed. 2019;32:e4019.
15. Zwanenburg A, Vallieres M, Abdalah MA, Aerts H, Andrearczyk V, Apte A, et al.
The image biomarker standardization initiative: standardized quantitative
radiomics for high-throughput image-based phenotyping. Radiology.
2020;295:328–38.
16. Ziegler E, Urban T, Brown D, Petts J, Pieper SD, Lewis R, et al. Open health
imaging foundation viewer: an extensible open-source framework for building





MAM drafted the manuscript and all authors contributed to the drafting or revising of
the manuscript and approved the final version.
FUNDING
NCITA is funded by a Cancer Research UK Accelerator Award (C42780/A27066
(University College London; PI Professor Shonit Punwani); C34326/A28684 (University of
Oxford; PI Professor Geoff Higgins); C1922/A28683 (University of Manchester; PI
Professor James O’Connor); C22479/A28667 (University of Cambridge; PI Professor Evis
Sala); C2536/A28680 (Imperial College London; PI Professor Eric Aboagye); C7273/
A28677 (Institute of Cancer Research, London; PI Professor Dow Mu Koh); C1519/A28682
(King’s College London; PI Professor Tony Ng). The Panorama Trial (NCITA Exemplar
study) received support from the Cancer Research UK KCL-UCL Comprehensive Cancer
Imaging Centre (C1519/A16463 (2013-18) C1519/A10331 (2008-13)).





The authors declare no competing interests.
M.A. McAteer et al.
1464
British Journal of Cancer (2021) 125:1462 – 1465
ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41416-021-01497-5.
Correspondence and requests for materials should be addressed to M.A.M.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2021
M.A. McAteer et al.
1465
British Journal of Cancer (2021) 125:1462 – 1465
